Publications by authors named "R Manoj"
Purpose: We set out to develop a publicly available tool that could accurately diagnose spinal muscular atrophy (SMA) in exome, genome or panel sequencing datasets aligned to a GRCh37, GRCh38, or T2T reference genome.
Methods: The SMA Finder algorithm detects the most common genetic causes of SMA by evaluating reads that overlap the c.840 position of the SMN1 and SMN2 paralogs.
Background: The efficacy and safety of the ultrathin BioMime sirolimus-eluting coronary stent (SES) system in treating single or multiple native coronary lesions, in-stent restenosis, and bifurcation lesions have been evidenced at 1 year.
Aims: We sought to investigate the long-term safety and efficacy of the BioMime SES in a real-world population with obstructive coronary artery disease (CAD).
Methods: The prospective, single-arm, multicentre meriT-2 trial enrolled 250 patients from 11 sites across India.
Article Synopsis
- Kyrle disease is an acquired perforating disorder linked to conditions like type 2 diabetes and chronic kidney disease, characterized by skin lesions that show transepidermal elimination of dermal contents upon histopathological examination.
- In the reported case, the patient exhibited only hyperuricemia as an abnormal lab finding, with no typical associated conditions present, making the cause of the disease unclear.
- Treatment focused on addressing the underlying issues; however, the patient saw improvement with medications like acitretin, dapsone, and topical corticosteroids, highlighting the need for more research on factors like hyperuricemia in cases lacking classic associations.
Article Synopsis
- Infections resistant to antibiotics, especially carbapenem-resistant ones, are a serious global health issue, particularly in cases of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP).
- The review explores sulbactam-durlobactam therapy (SUL-DUR), assessing its approval process, how it works, and its potential in treating these bacterial infections.
- SUL-DUR, known as Xacduro, has shown safety and effectiveness in clinical trials, making it a promising treatment alternative compared to traditional options like colistin for VAP, HAP, and related infections.